PUBLIC COMPANY
save$DYNDyne Therapeutics, Inc.
$DYN26.71+0.79%Waltham, MA, USupdated 13h ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Preclinical2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
- phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
- phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 22, 26SELLRhodes Jason P· −$2.97M↗
- Apr 22, 26SELLRhodes Jason P· −$1.49M↗
- Apr 22, 26SELLRhodes Jason P· −$1.17M↗
- Apr 22, 26SELLKersten Dirk· director−$53K↗
- Apr 22, 26SELLRhodes Jason P· −$29K↗
- Apr 21, 26SELLRhodes Jason P· −$2.78M↗
- Apr 21, 26SELLRhodes Jason P· −$1.39M↗
- Apr 21, 26SELLRhodes Jason P· −$1.10M↗
- Apr 21, 26SELLKersten Dirk· director−$166K↗
- Apr 21, 26SELLRhodes Jason P· −$31K↗
- Apr 21, 26SELLRhodes Jason P· −$27K↗
- Apr 21, 26SELLRhodes Jason P· −$15K↗
- Apr 21, 26SELLRhodes Jason P· −$12K↗
- Apr 21, 26SELLRhodes Jason P· −$301↗
- Apr 20, 26SELLRhodes Jason P· −$2.86M↗
- Apr 20, 26SELLKersten Dirk· director−$2.51M↗
- Apr 20, 26SELLRhodes Jason P· −$1.44M↗
- Apr 20, 26SELLRhodes Jason P· −$1.13M↗
- Apr 20, 26SELLRhodes Jason P· −$28K↗
- Apr 17, 26SELLKersten Dirk· director−$4.30M↗
🐶 Hiring Signal
News
- Capricor CEO won’t rule out legal action against FDA after negative adcommAfter an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior mot…biospace · 11d ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 1mo ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that